Compare Standard Lithium Ltd (SLI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Summit Therapeutics Inc — how do they compare? Standard Lithium Ltd trades at $2.43 (market cap $604.50M), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 20× Standard Lithium Ltd's market cap. Which is the better fit depends on your goals.
| SLI | SMMT | |
|---|---|---|
Market Cap | $604.50M | $12.06B |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $26.98 |
52-Week Low | $1.93 | $12.55 |
Enterprise Value | $467.42M | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLI trades at $2.41, down 4.74% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $48.40M in 2025, with negative ROE and ROA, but beat EPS estimates in two recent quarters. Positive news includes a $225M DOE grant and progress on its South West Arkansas lithium project, with institutional buying from Amundi (64.9% stake increase in Q1 2026 per SEC filing).
The outlook hinges on project execution, as SLI transitions to production with strong analyst support (100% buy ratings). Key risks include cash burn from negative operating cash flow and reliance on financing, but de-risking milestones and government backing offer upside if timelines are met.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
